Chiasma Inc.

75 articles about Chiasma Inc.

• Struggling Chiasma Chops 33% of Workforce After FDA Drug Rejection

  6/15/2016

• Chiasma Chief Says Firm May Challenge FDA Over Rare-Disease Drug Rejection

  5/12/2016

• Chiasma Crashes on FDA Drug Rejection of Mycapssa

  4/18/2016

• Chiasma Reviews 2015 Accomplishments And Outlines Core Objectives For 2016

  1/8/2016

• Chiasma Announces Addition Of James R. Tobin And John F. Thero To Board Of Directors

  11/30/2015

• Chiasma Reports Third Quarter 2015 Financial Results And Recent Business Highlights

  11/13/2015

• Chiasma To Present At Upcoming Investor Conferences

  11/11/2015

• Chiasma Supports Acromegaly Awareness With Launch Of New Online Resource For Patients And Caregivers

  10/30/2015

• Chiasma Reports Second Quarter 2015 Financial Results And Recent Business Highlights

  9/1/2015

• Chiasma Appoints William H. Ludlam, M.D., Ph.D., As Vice President Of Medical Affairs

  8/24/2015

• Chiasma Announces FDA Acceptance For Filing Of New Drug Application For Octreotide Capsules In Acromegaly

  8/17/2015

• Chiasma Expands Management Team With Announcement Of Anand Varadan As Chief Commercial Officer

  8/10/2015

• Chiasma Prices Initial Public Offering Of Common Stock

  7/16/2015

• Chiasma Submits New Drug Application To U.S. FDA For Octreotide Capsules In Acromegaly

  6/15/2015

• Chiasma Strengthens Management Team With Announcement Of Chief Financial Officer

  5/18/2015

• Chiasma Announces New Data For Investigational Octreotide Capsules To Be Presented At ECE 2015

  5/11/2015

• Chiasma Announces New Data for Investigational Octreotide Capsules To Be Presented At ECE 2015

  5/11/2015

• Chiasma Announces Mark Leuchtenberger As Chief Executive Officer

  3/16/2015

• With $70 Million in Pocket, Chiasma Hunts for New HQ in Newton or Cambridge

  3/10/2015

• Chiasma Announces New Data For Investigational Octreotide Capsules

  3/5/2015